The abstract is read at the publisher; the summary is JClub's.
Upifitamab labeling identifies sodium phosphate transporter NaPi2b (SLC34A2) as a highly specific AT2 marker, enabling high-purity isolation of both mouse and human alveolar type 2 cells.
- Why it matters: AT2 dysfunction is linked to multiple lung diseases, but existing isolation markers are limited by species differences and insufficient specificity, complicating flow sorting and magnetic-activated workflows.
- What they did: Using surface protein-restricted transcriptomics, the study pinpointed SLC34A2 and optimized detection with the humanized monoclonal antibody upifitamab for AT2 labeling compatible with flow cytometry and magnetic-activated isolation.
- The result: AT2 cells isolated with upifitamab can be cultured as organoids, grown as monolayers, or differentiated to AT1 cells, streamlining ex vivo alveolar biology and therapeutic development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.